Glaukos Corporation
http://www.glaukos.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Glaukos Corporation
Nicox’s NCX 470 Hits Phase III Endpoint In Glaucoma But Misses Superiority
NCX 470 demonstrates non-inferiority in intraocular pressure reduction versus latanoprost in the first of two Phase III studies, but does not meet a secondary endpoint that would have shown superiority.
Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
Execs On The Move: April 2022
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Execs On The Move, April 2022 Roundup: Shake Ups At Glaukos, Medtronic, BD And Globus
Executives On The Move will be running to a monthly schedule from now, with this edition covering medtech's executive changes for April.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice